Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955276 · ClinicalTrials.gov registry record
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
A clinical trial, sponsored by University of California, San Diego.
- Terminated
- Registry status
- 13
- Enrollment target
NCT03955276 is a clinical trial that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 13 participants.
The verdict
NCT03955276 was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular mutation profile will then be matched to existing, FDA-approved, targeted agents or to existing clinical trials using investigational agents for treatment of patients with incurable hematologic malignancies for whom no effective standard therapy exists or who have either exhausted or are intolerant of standard options.
Interventions
- OTHER Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2021-01-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955276
The ClinicalTrials.gov registry entry for NCT03955276 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician) is the first listed.
NCT03955276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03955276 about?
NCT03955276 is a clinical study titled "An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)". The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular m...
What is the current status of trial NCT03955276?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2019-02-07. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT03955276?
The interventions under investigation include: Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician) (OTHER).
Who is sponsoring clinical trial NCT03955276?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.